CONTACT
+91 80 2808 2808
info@biocon.com
Biocon  /  Investor Relations  /  Stock Exchange Disclosures  /  Press Release

PRESS RELEASE

FY 2024-25

Nov-24
14-Nov Biocon Academy Achieves 100% Placement within 2.5 hours for Quality Control Analytical Program & Biocon Academy also Concludes 5th edition of MCADDI – 5-day Residential Program for Industry Experts
Oct-24
30-Oct Biocon Q2FY25 Revenue at Rs 3,623 Cr, EBITDA at Rs 718 Cr
28-Oct Biocon Continues to be Among Science Magazine’s Top 10 Global Employers List
25-Oct Biocon Foundation Honored with ‘Doing Good for Bharat Awards 2024’ in ‘Healthcare Category’ for ‘eLAJ Smart Clinics’ by the CSR Box
08-Oct Biocon Biologics’ Commissioned Report Highlights Pathways to Increase Adoption of Biosimilars in LMICs
03-Oct Biocon Biologics Refinances USD 1.1 Billion (INR 93,468 million) Long Term Debt through USD Bonds and New Syndicated Facility
Sep-24
26-Sep Biocon Limited partners with Tabuk Pharmaceuticals to commercialize its Glucagon-like peptide-1 (GLP -1) products in the Middle East region
25-Sep Biocon Biologics Announces New Dermatology Data to Be Presented at EADV Congress 2024
Aug-24
29-Aug Biocon Biologics Secures Market Entry for Bmab 1200, a Proposed Biosimilar to Stelara®, in Europe, UK, Canada, and Japan
08-Aug Biocon Q1FY25 Revenue up 30% at Rs 4,567 Cr EBITDA up 117% at Rs 1,755 Cr Net Profit at Rs 660 Cr
May-24
24-May Biocon Limited signs exclusive licensing and supply deal for the commercialization of Liraglutide in South Korea with Handok Inc.
21-May Biocon Biologics Obtains U.S. FDA Approval for Biosimilar Aflibercept for Yesafili™. Enters U.S. Ophthalmology Market
16-May Biocon Q4FY24 Revenue at Rs 3,966 Cr, EBITDA at Rs 964 Cr; Net Profit (before exceptional items) at Rs 144 Cr
13-May Biocon Limited signs semi-exclusive distribution and supply deal for the commercialization of generic Saxenda® (Liraglutide) in Mexico with Medix
April-24
17-Apr Biocon Limited signs an exclusive licensing and supply agreement for generic Ozempic (Semaglutide) commercialization in Brazil with Biomm S.A.

FY 2023-24

March-24
27-Mar Biocon is the first generics company to obtain approval for diabetes drug, Liraglutide, in the U.K.
14-Mar Biocon Biologics Enters a Long-term Commercial Collaboration with Eris Lifesciences to Expand Patient Access in India
February-24
29-Feb Biocon Biologics Secures US Market Entry Date for Bmab 1200, a Proposed Biosimilar to Stelara®
20-Feb Biocon Included in S&P Global Sustainability Yearbook 2024
09-Feb Biologic Biologics Partners with Sandoz Australia for Biosimilars Trastuzumab and Bevacizumab
08-Feb Biocon Q3FY24 Revenue at Rs 4,519 Cr, Up 50%; Biosimilars Up 65%; Research Services Up 9%; EBITDA at Rs 1,492 Cr, Up 106%; Net Profit at Rs 660 Cr Pre-Paid USD 200 Mn towards Debt Reduction
05-Feb Oral Cancer Task Force’s Consensus Guidelines for Head & Neck Cancer Recognized Among 13 Worldwide Clinical Practice Guidelines
December-23
22-Dec Biocon Biologics Partners with Sandoz for the Distribution of “Adalimumab BS Subcutaneous Injection [FKB]” in Japan
19-Dec Biocon Academy Conducts its 8th Graduation Day, 112 Students with 77% Females across Four Programs Participate
16-Dec Biocon Biologics Concludes Integration of Acquired Biosimilars Business in ~120 countries
15-Dec Biocon Biologics Recognized as an Asia IP Elite for 2023, IPR Team adjudged as the Team of the Year
Novermber-23
30-Nov Biocon Biologics Successfully Completes Integration of Viatris’ Biosimilar Business in 31 Countries in Europe
10-Nov Biocon Q2FY24 Revenue at Rs 3,620 Cr, Up 52%; Biosimilars Up 97%; Research Services Up 18% EBITDA at Rs 900 Cr, Up 68%; Core EBITDA at Rs 1,100 Cr, Up 35% Net Profit at Rs 126 Cr, Up 168%
08-Nov Biocon Biologics Announces Divestment of Two Non-Core Branded Formulations – India Business Units
October-23
31-Oct Biocon Ranked No. 8 Among Science Magazine’s Best Employers in Global Biotech and Pharma Sector
19-Oct Kedar Upadhye Appointed as New CFO of Biocon Biologics Current CFO MB Chinappa to take on a Strategic Finance role at Biocon Group
06-Oct Biocon Limited signs commercialization agreement with Juno Pharmaceuticals in Canada
September-23
18-Sep Biocon Board Appoints Peter Bains as Group CEO
07-Sep Kiran Mazumdar-Shaw appointed as member of the Court of Regents at the Royal College of Surgeons of Edinburgh
06-Sep Biocon Biologics Continues to Expand Global Footprint, Completes Integration of Viatris Biosimilars’ Business In North America, Ahead of Schedule
01-Sep Biocon Limited announces the acquisition of a manufacturing facility of Eywa Pharma Inc.
August-23
10-Aug Biocon Q1FY24 Revenue at Rs 3,516 Cr, Up 59%; Biosimilars Up 106%; Research Services Up 25% EBITDA at Rs 808 Cr, Up 69%; Core EBITDA at Rs 936 Cr, Up 42% Net Profit at Rs 101 Cr
10-Aug Biocon Foundation and Shakti Sustainable Energy Foundation organize Cities and Climate Action Workshop
04-Aug Biocon Biologics Announces Key Leadership Appointments
July-23
27-July Biocon Foundation Releases Second Edition of Consensus Guidelines for Head & Neck Cancer Marks the World Head & Neck Cancer Day at the OCTF Conference
24-July Biocon Biologics Announces Positive CHMP Opinion for YESAFILI®, Biosimilar Aflibercept
05-July Biocon Biologics Expands Footprint in Emerging Markets Takes Over the Commercialization of Biosimilars Business from Viatris in 70+ countries
03-July After Five Years of Successful Experience Internationally, Biocon Biologics’ Hulio® Biosimilar to Humira®, Now Available in the United States
June-23
30-June Biocon Group concluded the month-long sustainability initiatives commemorating ‘World Environment Day’ initiated with ‘Nature Positive’ Campaign
May-23
23-May Biocon Q4FY23 Revenue at Rs 3,929 Cr, Up 59%; Biosimilars Up 114%; Research Services Up 31%
April-23
25-Apr Serum & Biocon Biologics Agree to Restructure Equity Investment
05-Apr Biocon Academy Conducted Graduation Ceremony For 185 Students across Four Programs
04-Apr Biocon Awarded a Silver Medal by EcoVadis for its Sustainability Accomplishments

FY 2022-23

March-23
28-Mar Biocon Biologics Wins the ‘ABEA : Bioprocessing Excellence in South Asia’ Award
February-23
14-Feb Biocon Q3FY23 Revenue at Rs 3,020 Cr, Up 36%; Biosimilars Up 54%; Research Services Up 23%; Generics Up 18%
January-23
24-Jan Biocon Foundation Wins the Prestigious ‘IHW Gold Award for Diseases Screening Initiative of the Year’ for 2022
December-22
22-Dec Biocon Biologics Recognized as a Company with Great Managers; Two Managers conferred with individual ‘Great Managers Award 2022’
14-Dec Biocon Limited initiates clinical study of Itolizumab for Ulcerative Colitis in India
05-Dec Shreehas Tambe Appointed as Managing Director & CEO of Biocon Biologics Limited
Novermber-22
29-Nov Biocon Biologics Completes Acquisition of Viatris’ Global Biosimilars Business
24-Nov Biocon Limited enters into a commercialization agreement with Zentiva in Europe
14-Nov Biocon Q2FY23 Revenue at Rs 2,384 Cr, Up 23%; Core EBITDA at Rs 816 Cr, Up 34% Gross R&D Spend at Rs 252 Crore, Up 52%
11-Nov Biocon Biologics Features in the Prestigious ASIA IP ELITE List for 2022
October-22
31-Oct Biocon Ranks at No. 8 in ‘Global Top Employers’ List by the U.S. Science Magazine
17-Oct Biocon Biologics Out-Licenses Two Biosimilar Assets to Yoshindo for Commercialization in Japan
07-Oct Biocon Foundation Receives ‘Mahatma Award 2022 for Excellence in Social Good’
September-22
24-Sep Kiran Mazumdar-Shaw Awarded with H.K. Firodia Lifetime Achievement Award 2022 for Excellence in Science & Technology
August-22
05-Aug Biocon Sdn. Bhd. Enters Malaysia Book of Records as the First & the Largest Integrated Insulin Manufacturing Facility
July-22
27-July Biocon Q1FY23 Revenue at Rs 2,217 Cr, Up 23%; Net Profit at Rs 144 Cr, Up 71%; Core EBITDA at Rs 660 Cr Up 25%; Biosimilars Up 29%; Generics Up 19%; Research Services Up 8%
June-22
09-June University of Glasgow officially Opens Mazumdar Shaw Advance Research Centre
May-22
19-May Biocon Biologics and Viatris Launch Abevmy® (bBevacizumab), Their Third Oncology Biosimilar, in Canada
April-22
28-Apr Biocon Q4FY22 Revenue at Rs 2,476 Cr, Up 21%; Core EBITDA at Rs 815 Cr, Up 37% ; PBT(before Exceptional Items) at Rs 384 Cr, Up 9% Biosimilars Up 48% at Rs 982 Cr; Generics Up 26% at Rs 717 Cr; Research Services Up 15% at Rs 758 Cr. FY22 Revenue at Rs 8,397 Cr, Up 14%; Core EBITDA Up 18% at Rs 2,669 Cr; PBT (before Exceptional Item) at Rs 1094 Cr, Up 4%
26-Apr Biocon Biologics’ Insugen® Awarded a Three-Year Contract by Ministry of Health, Malaysia
01-Apr Biocon Biologics’ Partner Receives Positive EU CHMP Opinion for Biosimilar Human Insulin for IV Infusion

FY 2021-22

March-22
29-Mar University of Glasgow Names their Flagship Research Centre After John Shaw and Kiran Mazumdar-Shaw
23-Mar Kiran Mazumdar-Shaw Elected as the Fellow of Royal Society of Edinburgh (RSE)
February-22
27-Feb Biocon Biologics to Acquire Viatris’ Biosimilars Assets for up to USD 3.335 billion in Stock and Cash
January-22
20-Jan Biocon Q3FY22 Revenue at Rs 2,223 Cr, Up 18%; EBITDA at Rs 537 Cr, Up 25%; Biosimilars Up 28% at Rs 981 Cr; Research Services Up 10% at Rs 641 Cr; Generics Up 7% at Rs 607 Cr
December-21
30-Dec Biocon Biologics* Partner Viatris Wins U.S. Court Decisions on Sanofi Appeals for Lantus® Device Patents
23-Dec Clinical Study for Itolizumab in Lupus Nephritis Initiated in India, Post DCGI Approval
07-Dec Biocon Ltd partners with Tabuk Pharmaceuticals to commercialise its speciality generic medicines in the Middle East
01-Dec Biocon Enters Prestigious Dow Jones Sustainability Emerging Markets Index
November-21
16-Nov Biocon Biologics and Viatris Announce Launch of Interchangeable SEMGLEE® (insulin glargine-yfgn) Injection and Insulin Glargine (insulin glargine-yfgn) Injection
15-Nov Biocon Biologics Collaborates with RSSDI to Expand Access to its Insulins for Children with Type 1 Diabetes on World Diabetes Day
October-21
21-Oct Biocon Q2FY22 Revenue up 10% at Rs 1,945 Cr; EBITDA up 35% at Rs 551 Cr; Net Profit (before exceptional items) up 11% at Rs 188 Cr;
21-Oct Appointment of Dr. Eric Vivek Mazumdar as Non-Executive, Non-Independent Director of the Company
21-Oct Biocon Biologics’ First-Ever Interchangeable Biosimilar Insulin Glargine, Co-Developed with Commercial Partner Viatris, Preferred on Express Scripts’ Largest Formulary in US
04-Oct Biocon expands its Generic Formulations portfolio with the launch of Everolimus tablets in the US
September-21
16-Sep Biocon Biologics and Serum Institute Life Sciences Announce Strategic Alliance
July-21
29-July Biocon Biologics and Viatris Inc. Receive Historic Approval for First Interchangeable Biosimilar Semglee® (insulin glargine-yfgn injection) for the Treatment of Diabetes
26-July Biocon Biologics Partners with Adagio Therapeutics to Advance Antibody for the Prevention and Treatment of COVID-19
22-July Biocon Q1FY22 Revenue at Rs 1,808 Cr, Up 6%; EBITDA at Rs 437 Cr; Biosimilars Up 10 % at Rs 758 Cr; Research Services Up 41 % at Rs 595 Cr;
April-21
29-Apr Biocon Q4FY21 Revenue at Rs 2,044 Cr, Up 26%; EBITDA at Rs 641 Cr; Up 68% Net Profit (before exceptional item & discontinuing operations) at Rs 257 Cr; Biosimilars Up 53% at Rs 664Cr; Research Services Up 8% at Rs 659 Cr; Generics Up 3% at Rs 578 Cr. FY21 Revenue Up 14% at Rs 7,360 Cr; EBITDA Up 8% at Rs 1,907 Cr; Net Profit (before exceptional item & discontinuing operations) at Rs 754 Cr.
28-Apr Biocon Biologics’ New Monoclonal Antibodies Manufacturing Facility Wins ISPE’s 2021 Facility of the Year Honorable Mention Award

FY 2020-21

Mar-21
29-Mar Biocon Pharma partners with Libbs Farmaceutica to launch generic formulations in Brazil
02-Mar Biocon Biologics Appoints Susheel Umesh as Chief Commercial Officer for Emerging Markets
01-Mar Biocon Biologics Promotes Shreehas Tambe to Deputy Chief Executive Officer
01-Mar Biocon Biologics and Viatris Inc. Receive CHMP Nod for Abevmy®, a Biosimilar to Avastin® (Bevacizumab)
Feb-21
16-Feb Biocon Biologics Joins Hands with IDF in its Mission to Promote Diabetes Care, Prevention and effective Management Worldwide
04-Feb Biocon Biologics to offer its Oncology Biosimilars through Cancer Access Partnership in over 30 countries, Will enable access to Trastuzumab & Pegfilgrastim in Africa & Asia
Jan-21
21-Jan Biocon Q3FY21 Revenue at ₹ 1,879 Crore, Up 7%; EBITDA at ₹427 Crore; Net Profit at ₹169 Crore; Biosimilars up 11% at ₹769 Crore; Research Services up 13% at ₹585 Crore; Generics down 3% at ₹561 Crore
21-Jan Professor Peter Piot Joins the Board of Biocon Biologics Limited as an Independent Director
07-Jan Biocon Biologics Receives Rs 555 Cr (USD 75 Million) Capital Injection from ADQ
Dec-20
28-Dec Biocon expands generic formulations portfolio with the launch of Tacrolimus capsules in the US
15-Dec Biocon Biologics signs an MoU with CSSC in Tanzania for Mission 10 cents
Nov-20
07-Nov Biocon Biologics Receives USD 150 Million Capital Injection from Goldman Sachs, Transaction Values Biocon Biologics at USD 3.94 Billion
Oct-20
30-Oct Biocon Ranked Among Top 5 Biotech Employers Globally
22-Oct Press Release on financial results for the Quarter ended September 30, 2020
08-Oct Biocon Foundation Signs MoU with Bangalore Metro to Contribute Towards Building Metro Station in Hebbagodi
Sep-20
22-Sep Biocon appoints Anupam Jindal as its Chief Financial Officer
Aug-20
31-Aug Biocon Biologics and Mylan Announce Launch of Semglee™ (insulin glargine injection) in the U.S. to Expand Access for Patients Living with Diabetes
14-Aug Disclosure of material impact of COVID 19 pandemic on the Company
03-Aug Execution of SHA and SSA with Tata Capital Growth Fund II – Disclosure pursuant to Regulation 30 of SEBI Regulations, 2015
Jul-20
31-Jul Tata Capital Growth Fund to Invest ~USD 30 Million (Rs 225 Crore) in Biocon Biologics for an Equity Stake of 0.85%, Deal Values Biocon Biologics at USD 3.5 Billion
23-Jul Press Release on financial results for the quarter ended June 30, 2020.
21-Jul Biocon Biologics and Voluntis Join Hands for Global Collaboration on Digital Therapeutics for Insulins
11-Jul Biocon’s Breakthrough Drug Itolizumab Receives DCGI Nod for its Use in Moderate to Severe COVID-19 Patients
Jun-20
22-Jun Biocon Pharma and DKSH Collaborate to commercialize seven generic formulations in South East Asia markets
12-Jun Biocon and Mylan Announce U.S. FDA Approval of Semglee™ (insulin glargine injection)
05-Jun Kiran Mazumdar-Shaw wins EY World Entrepreneur of the Year™ 2020 Award. She is the first woman entrepreneur from India and third Indian to win this title in WEOY Award’s 20-year History
01-Jun Biocon’s* Partner Mylan Receives Favourable Ruling from U.S. PTAB on Sanofi’s Four Device Patents for Lantus® SoloSTAR®
May-20
27-May Biocon Biologics Receives DCGI Approval for Emergency Use of CytoSorb® to Treat Critical COVID-19 Patients U.S. FDA recently approved CytoSorb for emergency use in COVID-19 patients
19-May Biocon Biologics Receives EU GMP Certification for Multiple Biosimilars Manufacturing Facilities in Bengaluru; Expands its Manufacturing Capacity Includes Drug Substance and Drug Product Facilities for Pegfilgrastim, Trastuzumab, and Bevacizumab
14-May Biocon Earnings Q4FY20 Revenue Up 6% at Rs 1,644 Cr; EBITDA Down 11% at Rs 382 Cr; Net Profit Down 42% at Rs 123 Cr
Apr-20
28-Apr Biocon and Mylan Launch Fulphila®d, Biosimilar Pegfilgrastim, in Canada.
14-Apr Biocon and Mylan Launch Fulphila®, Biosimilar Pegfilgrastim, in Australia
01-Apr Biocon’s Insulin Manufacturing Facility in Malaysia Receives EIR from U.S. FDA with Voluntary Action Indicated (VAI) Classification, Inspection Stands Closed
ARCHIVES

FY: From April 1 – March 31

Know more
about us

>> Generics
>> Biocon Academy
>> Biocon Malaysia

NOVEL BIOLOGICS
BIOSIMILARS
RESEARCH SERVICES
OUR CULTURE
BIOCON FOUNDATION

Report adverse event/ side effects and/or product complaints for Biocon products.


Click here to report adverse event/side effects/product complaints and/or submit medical queries for Biocon Biologics Limited & BBL Affiliate products.

Click here to report adverse event/side effects/product complaints and/or post medical queries for Biocon Limited, Biocon Pharma Limited, Biocon Pharma Inc., Biocon Pharma UK Limited, Biocon Pharma Malta Ltd and Biocon FZ LLC products.





* Safe Harbour | Privacy Policy | Terms of Use © 2024, Biocon. All Rights Reserved
Share
Leaving the Biocon site!

You are now leaving the Biocon website for a Biocon affiliate site or third party site that is solely responsible for its content, including its compliance with guidelines applicable in certain geographies. Links to Biocon affiliate sites and third party sites are provided as a resource to our visitors and may not be governed by the same regulatory requirements applicable to this site and unaffiliated third party sites are subject to their own terms and data protection notices and practices. Moreover, if their third party site is subject to other country laws, regulatory requirements, data protection requirements or medical practices may differ between countries and the information provided therein may not be suitable for use in your country.

Agree >>